ISRCTN43757325进行中（未招募）未知
ThinkCancer!: A pragmatic randomised controlled phase III trial of a novel behavioural intervention for primary care teams to promote earlier cancer diagnosis with embedded process and economic evaluation?
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •General practices will primarily be recruited from Wales, topped up with practices from North West of England. We will recruit 8-10 practices from each of the seven Health Boards in Wales, and 8-10 from North West England; this conservative estimate is informed by feasibility study recruitment. Wales and North West England have similar regional demography; with higher deprivation and cancer rates compared with other UK areas ?(NWCR, 2021b, 2021a)?. If recruitment is challenging, we propose to extend the study into South West England. Networks and contacts established through the feasibility study will be maintained in order to maximise recruitment across Wales, and regional Clinical Research Network (CRN) teams will assist in recruiting the practices across all of the centres.
排除标准
- •All practice types will be included
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 µg, 120 µg, and 200 µg in Healthy Adolescents Aged 11 to 18 YearsThe test is a vaccine. The subjects are healthy adolescents.MedDRA version: 14.1Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-007789-51-PLPfizer Inc715
进行中（未招募）
不适用
A clinical study to test the safety and immune response of a vaccine against a bacteria causing meningitis B at doses of 60 µg, 120 µg, and 200 µg in healthy adolescents aged 11 to 18 YearsPrevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in adolescents and young adults, aged 10 through 25 years.MedDRA version: 17.1Level: LLTClassification code 10004049Term: Bacterial meningitisSystem Organ Class: 100000004862EUCTR2008-007789-51-Outside-EU/EEAWyeth Research Division of Wyeth Pharmaceuticals Inc.539
已完成
1 期
To evaluate safety and tolerability after multiple oral doses of AZD1656 in type 2 diabetes patients on top of metformiCTRI/2009/091/000774AstraZeneca AB, 151 85 Södertälje, Sweden24
进行中（未招募）
不适用
A randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirferidone in patients with Idiopathic Pulmonary Fibrosis - NDIdiopathic pulmonary fibrosis IPF ICD X J84.1other interstitial pulmonaryMedDRA version: 6.1Level: PTClassification code 10037383EUCTR2006-000252-41-ITINTERMUNE325
进行中（未招募）
1 期
A Study of the safety and effectiveness of ARGX-113 in Patients with Primary Immune ThrombocytopeniaEUCTR2016-003038-26-GBArgenx BVBA38